SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.68-2.4%Dec 12 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: IRWIN JAMES FRANKEL who wrote (6240)4/29/2002 11:16:42 AM
From: keokalani'nui  Read Replies (1) of 52153
 
Marketing department worked over the weekend to bring you this.

SG Cowen names AMGN their "Bottom Line Action Idea of the Week", saying that the co has accelerating rev growth, great product visibility, and no FDA, clinical or patent risk; upcoming catalysts include: Neulasta launch (ongoing), ASCO (May), completion of the IMNX merger (June), and the U.S. approval of Aranesp in oncology (2H02).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News